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 The Editor 
European Journal of Cancer 
 
Dear Sir 
 
Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the 
breast. 
 
I should be grateful if you would consider the attached manuscript for publication in 
the European Journal of Cancer. This is a resubmission following appeal (previous 
manuscript No EJC-D-13-01702) after we had gathered additional data on hospital to 
hospital variation in outcomes. 
 
We believe our study makes the following important observations on current breast 
screening practice and has wider implications for other multi-institution studies such 
as clinical trials: 
 
1. We have quantified adverse surgical outcomes in screen-detected DCIS 
examining data from more than 8,000 patients – this has never been done 
before. 
2. Having looked at a range of variables we have identified radiology/pathology 
size mismatch as the likely culprit at the root of these adverse outcomes. 
3. There is a wide and significant variation among hospitals in the frequency of 
these outcomes but the case mix (as deduced by looking at the same variables 
again) is the same. 
4. We conclude that it is likely that practice variation is at the heart of the 
problem and that we can learn from the best.  
 
Our study provides an evidence base for benchmarking future practice in this area. 
 
The study relies heavily on statistical analysis, particularly comparison of agreement 
between two methods of measurement (radiology and pathology) and analysis of 
variation among hospitals. We have used Altman Bland difference plots and one 
tailed Anova testing respectively for these. The inter-hospital analysis was restricted 
to the top quartile of hospitals submitting cases (in terms of numbers of cases 
registered for the Audit) however this quartile accounts for 80% of the patients in the 
audit. We have also explored whether the same hospitals perform similarly for a 
variety of measured outputs i.e. is a hospital equally bad at one area of practice as 
another or are hospitals good at some areas of practice and bad at others? We have 
tested this by comparing rates of hospital’s various outputs. There was only one 
significant finding here – hospitals with high overall mastectomy rates also have 
higher failed breast conservation rates.  
 
We have included an Appendix giving a fuller explanation of these methods. 
 
Cover Letter
We have a substantial amount of additional material that has been included in a 
supplementary file. The bulk of these data relate to questions that will inevitably be 
asked about the study – demographics and detailed comparison of key pathological 
variables, for example, all of which underline the fact that it is not the biology of the 
disease that explains the differences in outcome but how the disease is managed in 
different units. If the study is deemed suitable for publication and the Editors deemed 
it preferable to include this information in the main paper I would happily revise the 
manuscript accordingly. 
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ABSTRACT 
Background 
The Sloane Project is the largest prospective audit of ductal carcinoma in situ (DCIS) 
worldwide, with over 12000 patients registered between 2003 and 2012, accounting 
for 50% of screen-detected DCIS diagnosed in the UK over the period of accrual. 
Methods 
Complete mutidisciplinary data from 8313 patients with screen-detected DCIS were 
analysed for surgical outcome in relation to key radiological and pathological 
parameters for the cohort and also by hospital of treatment. Adverse surgical 
outcomes were defined as either failed breast conservation surgery (BCS) or 
mastectomy for small lesions (<20mm) (MFSL). Inter-hospital variation was analysed 
by grouping hospitals into high, medium and low frequency for these two adverse 
outcomes. 
Results 
Patients with failed BCS or MFSL together accounted for 49% of all mastectomies. 
Of 6633 patients embarking on BCS, 799 (12.0%) required mastectomy. MFSL 
accounted for 510 (21%) of 2479 mastectomy patients. Failed BCS was associated 
with significant radiological under-estimation of disease extent and MFSL significant 
radiological over-estimation of disease extent. There was considerable and significant 
inter-hospital variation in failed BCS (range 3-32%) and MFSL (0-60% ) of a 
hospital's BCS/mastectomy workload respectively. Conversely, there were no 
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differences between the key radiological and pathological parameters in high, medium 
and low frequency adverse-outcome hospitals.  
Conclusions 
This evidence suggests significant practice variation, not patient factors, is responsible 
for these adverse surgical outcomes in screen-detected DCIS. The Sloane Project 
provides an evidence base for future practice benchmarking . 
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INTRODUCTION 
 
The recent Independent Breast Screening Review in England 
[1,2]
 recommended 
improving screening and pathology techniques in the diagnosis of breast cancer and 
made specific reference to the The Sloane Project, a prospective UK audit of patients 
with screen-detected non-invasive carcinomas and atypical hyperplasias of the breast 
detected by the National Health Service Breast Screening Programme (NHS BSP), 
named in memory of the late Professor John Sloane.
[3] 
 
 
We have identified four main clinically relevant surgical outcomes in the treatment of 
DCIS: successful conservation, failed conservation, mastectomy for lesions <20mm 
and mastectomy for lesions ≥20mm and we have defined failed breast conservation 
surgery (BCS) and mastectomy for small lesions (MFSL) as adverse surgical 
outcomes. In the management of DCIS, precise imaging, primarily through 
mammographic assessment of microcalcifications, including nature, location and 
extent, combined with careful multidisciplinary discussion of each patient is critical in 
planning appropriate surgery. The three most important features for disease 
behaviour, and thus clinical management, are: lesion size, cytonuclear grade (grade) 
and width of tumour-free margins. Some randomised clinical trials have indicated that 
additional features may predict local recurrence, such as the architectural pattern of 
DCIS and the presence of necrosis.
 [4-6]
 . 
 
We have previously shown that pathologists assess the extent of DCIS accurately in 
specimens from breast conserving surgery (BCS) but less so in mastectomies.
[7]
  
Using this same methodology with a much larger dataset, we have now studied the 
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treatment of DCIS diagnosed in the UK NHS BSP, analysing radiological and 
pathological factors according to surgical outcome and then by hospital of treatment. 
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PATIENTS AND METHODS  
 
Sources of data  
 
Eighty two of 94 (87%) UK NHS breast screening units submitted data. Each clinical 
specialty (radiology, surgery, histopathology, radiotherapy) contributed specialty-
specific data relating to diagnosis and treatment using specially designed proformas.  
 
Patient population 
 
We report on data for the entire audit period, April 2003 – March 2012, on over 8000 
patients with complete datasets. All patients had screen-detected DCIS, alone or with 
atypical ductal hyperplasia (ADH) and/or lobular in situ neoplasia (LISN), and were 
aged between 46 and 83 years at diagnosis, with a median age of 60. Patients were 
treated in 218 hospitals. 
 
Variables 
 
Surgical data included the number and type of operations and nature of the final 
surgery. We excluded therapeutic mammoplasty and diagnostic biopsy patients from 
the analysis of patients with a single breast conserving surgery (BCS) procedure. 
When a patient had multiple operations, the final disease extent was estimated from 
summation of the different specimens. The main pathology and radiology data items 
examined are detailed in the results.  
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We analysed specimen weight and disease location (whether subareolar or not) and 
radiological calcification. Radiological disease extent was recorded in two dimensions 
on both the mediolateral oblique and craniocaudal views and the maximum extent 
used for comparison of radiological and pathological estimation of size.  
 
For the analysis of inter-hospital variation we examined frequency of operation type 
for the top quartile of hospitals (by total numbers of cases submitted) and the hospital 
rankings by frequency of failed BCS and MFSL, to determine whether there was 
overlap for either adverse outcome. We further analysed our data by frequency group 
(high, medium and low) for the two adverse outcomes.  
 
Data analysis and statistical methodology 
 
All data were entered and held securely at the West Midlands Cancer Screening QA 
Reference Centre. This analysis was performed on a download dated 8
th
 February 
2013. Hypotheses were prospectively chosen by the authors. Data were analysed 
using “Analyse IT” v 2.20 for Microsoft Excel . Tests were deemed significant 
with p value <0.05. Student’s T test was used to compare groups of data where 
normally distributed. The chi squared test was applied to test frequency distributions 
across defined groups of data. Agreement between pathology and radiology size 
estimations was assessed using Altman Bland difference plots where the difference 
between the radiological and pathological size for any individual was plotted against 
the mean of the two values. The systematic bias in any group of paired measurements 
is the mean of all the differences - positive or negative. 
[8] 
Variance when normally 
distributed was measured using a one-tailed analysis of variance (Anova) test. 
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Homogeneity of variance was assessed using Hartley’s F Max test. Pearson’s 
correlation was used to compare hospitals’ frquencies for various operations. 
 
See Appendix 4 for further description of these statistical methods. 
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RESULTS 
Data relating to case distribution, demographics, operation type, grade and margins 
are detailed in the supplementary file (supplementary-data.doc). 
 
Patient accrual 
 
The accrual of the 8313 patients between 2003 and 2012 in the study set (see below) 
is shown in Figure 1. There was no difference in the accrual profile of operative 
subgroups in comparison to the overall accrual profile over time. 
 
Completeness of data 
 
A four-specialty dataset is available for 8313 (66%) of the 12623 patients. Data were 
near-complete following data cleaning. For example, the Altman Bland analysis of the 
3946 patients in the single operation BCS group had radiological and pathological 
size measurements for 3894 patients (98.6%). The size and/or grade were recorded for 
8233 (99%) cases. The lowest levels of completeness applied to ER measurements 
(54%); ER is not mandated in the UK DCIS pathology minimum dataset.  
 
Surgery, extent of disease, grade, and pathological/radiological size correlations for 
the different operation types 
 
The data relating to operation type are summarised in Table 1. 
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5834 (70%) of patients, including those who underwent therapeutic mammoplasty and 
diagnostic biopsy (47 and 349 patients respectively), were treated by BCS whilst 2479 
(26%) had mastectomy. 57 patients had successful BCS after more than two 
operations (range 3-5). Patients who had successful BCS at a single operation had 
significantly less extensive disease than those achieving successful conservation at 
two operations (12mm vs 17mm) (T test, p=<0.0001). The proportion of high grade 
disease and agreement between pathological and radiological size estimates was 
similar in both groups (Altman Bland bias of 2.95mm and -0.32mm respectively).  
 
799 patients with failed BCS subsequently requiring mastectomy accounted for 12% 
of the total BCS group and were notable for having a disease extent and grade 
distribution similar to those undergoing primary mastectomy. In patients with failed 
BCS there was poor agreement between pathological and radiological size estimation, 
with radiology underestimating disease extent as demonstrated by a negative Altman 
Bland bias of 13.49mm. 86 (10.8%) of these patients had lesions <20mm (see below). 
Figure 2. 
 
There were 510 (21%) mastectomies for patients with disease histopathologically 
measuring <20mm. This could not be explained either by the location within the 
breast (11.3% of these were retroareolar vs 11.1% for mastectomy overall). 
Mastectomy weight for specimens with DCIS lesions <20mm was lower than for for 
DCIS ≥20mm (median 570gm, inter-quartile range (IQR) 521.25 vs 626gm, IQR 
503.08 (T test; p=0.017). Notably, in this small-lesion group there was evidence of 
substantial overestimation of radiological size with an Altman Bland bias of 
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19.86mm. Figure 3. There was no difference in grade distribution in this subset in 
comparison with all mastectomies. 
 
The Altman Bland bias was calculated for each operative subgroup for those 
specimens where specimen slice radiography had been carried out. There was no 
significant difference between those cases where slice radiography had been 
employed and those where it had not. 
 
Mammographic calcification 
 
There was no difference in frequency or pattern of mammographic calcification in the 
operative subgroups. 
 
Inter-hospital variation: case numbers, operation type and reported grade 
 
There was a wide range in the number of cases submitted by the 218 different 
hospitals. The median number of patients was 10 (range 1 – 387; top quartile 50-387 
in 57 hospitals). These 57 hospitals accounted for 6691 of the 8313 (80%) of the 
patients in the study. 
 
1. Inter-hospital variation – the top quartile (57 hospitals): 
 
The proportions of the different operation types varied substantially between 
hospitals. Mastectomy rates ranged from 14-65% and for failed BCS and MFSL the 
ranges were 3-32% and 0–60% respectively (shown in Table 2). The inter-hospital 
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variance between failed BCS vs successful BCS operations was significant (Anova 
test, p=<0.0001). There were insufficient numbers to carry out an inter-hospital 
variance analysis for the mastectomy operative subgroups. There was a significant 
correlation between a hospital’s overall mastectomy rate and its rate of failed BCS 
(Pearson’s correlation, r=0.70; p=<0.0001). There was no correlation (positive or 
negative) between a hospital’s failed BCS rate and MFSL rate (Pearson’s correlation, 
r=0.11; p=0.41).  
 
2. Inter-hospital variation – the top quartile of hospitals analysed as three frequency 
subgroups (high, medium and low) for the two adverse outcomes: 
 
The top quartile of 57 hospitals was compared in 3 groups of high, medium and low 
frequency (19 each). The differences in mean frequency for each 19-hospital 
subgroup both for failed BCS and MFSL (high v medium, medium v low, high v low) 
were all highly significant (chi squared test; p=<0.0001). Analysis of the principal 
demographic, pathological and radiological variables (including Altman Bland bias) 
for each of the frequency groups showed no significant differences. (Table 3) There 
was little overlap in the hospitals’ frequencies of failed BCS and MFSL respectively 
(4/19 hospitals in the high frequency and 5/19 in the low frequency groups).  
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DISCUSSION 
 
This is the largest audit of DCIS in a population-based breast screening programme 
and the first to quantify the magnitude and significance of the problems of under-
estimation or over-estimation of disease extent in relation to operative outcome. A 
desire to conserve the breast, where possible, resulting in failure of conservation 
surgery on occasion may be inevitable. Likewise it is hard to envisage a service when  
mastectomy was never carried out for a small lesion, although for one of the study 
hospitals this was the case.  
 
Although nearly 90% of DCIS patients treated with BCS achieved successful breast 
conservation, usually after a single operation, the group of patients with failed BCS 
comprises one third of all patients who undergo mastectomy in this study. Conversely, 
a sizeable subset (21%) of patients undergoing mastectomy had lesions <20mm. 
Although these latter patients had smaller breasts (median 570 vs 626gm) than the 
large-lesion mastectomy subgroup, substantial over-estimation of the disease extent 
appears to drive decision-making, particularly given the range of mastectomy rates. 
Furthermore, specimen weight and lesion location considerations cannot account for 
variation by hospital. 
 
Data Quality 
 
Central review of Sloane Project pathology has not been performed. The audit, 
however, represents the reality of current quality-assured NHS BSP pathology 
practice in the UK. The NHS BSP has strict audit protocols and outputs are closely 
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monitored and published annually. The very large number of patients, even in sub-
group analysis, allows important messages to emerge. Our ability to band hospitals by 
frequency of adverse outcome also allows us to eliminate much of the “noise” of 
inter-hospital variability for single data items.  
 
Variation in practice among hospitals 
 
The wide variation in mastectomy rates and the positive correlation with failed BCS is 
concerning. While patient choice may be a factor, it is unlikely to explain completely 
the substantial differences seen between hospitals. Data from the NHS BSP indicate 
that patient choice accounts for just 11% of mastectomies for DCIS.
[9]
 The 
considerable variation in use of mastectomy for DCIS in different hospitals gives an 
opportunity to identify best practice and set criteria and measurable standards for the 
future. DCIS represents 20.3% of screen-detected breast cancer and addressing 
surgical adverse outcomes for this disease has the potential of significantly reducing 
screening-related morbidity. Early in the Sloane Project, the variation in practice 
relating to oestrogen receptor (ER) assessment and specimen handling was described. 
[10, 7] 
The finding that the accrual profile of the different operative subgroups is the 
same as the overall accrual profile for the audit demonstrates that there has been no 
change in the various operative outcomes over time and that adverse surgical 
outcomes are not simply a historic problem. 
 
Radiological under-estimation and over-estimation of disease extent 
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A question that must be asked in order to address this clinical issue is whether the 
mismatch between radiology and pathology size assessment lies predominantly with 
radiological or pathological interpretation.  
 
Block-taking and pathological disease mapping is more difficult in mastectomy than 
in BCS specimens 
7
; this is indicated by an Altman Bland bias of 9.9mm in the 
primary mastectomy group. The substantial differences of Altman Bland bias in the 
different mastectomy (and BCS) subgroups is key to better understanding this 
problem. The disparity is particularly stark between the mastectomy subgroups for 
small and larger lesions and also failed BCS compared to the other BCS subgroups. If 
specimen handling methodology was an important factor in improving the agreement 
between the pathological and radiological assessment of disease extent then the more 
accurate block selection afforded by the application of specimen slice radiography 
should improve the Altman Bland bias. However, use of slice radiography does not 
appreciably improve the agreement between radiological-pathological DCIS size 
assessment, indicating pathological specimen-handling methodology is unlikely to 
account for the variation in size estimation. 
 
The pre-operative multidisciplinary review meeting should recommend the most 
appropriate surgical procedure for each patient. These data indicate that in a 
proportion of women this decision was inappropriate, at least in retrospect.  Since 
there were no appreciable differences in the case-mix in high, medium and low 
frequency hospital subgroups for these adverse outcomes it suggests that the 
multidisciplinary discussion could be more critical, with detailed appraisal of both the 
radiological analysis of calcification-morphology combined with pathological 
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analysis of calcification-type seen in the pre-operative core biopsy sample. 
Specifically, there is an opportunity to drill down on the detailed association of the 
calcification with the histology, for example regarding whether microcalcification is 
also present in adjacent benign lesions, and assessment as to how much DCIS is not 
calcified histologically. To minimise inappropriate mastectomy for small lesions the 
threshold for mapping the lesion extent with more than one biopsy should be 
considered where mastectomy is proposed based on radiological findings. 
 
MRI is not routinely used for the pre-operative assessment of DCIS. While MRI is 
more accurate than mammography in high grade disease, beneficial effects on 
outcomes have not been demonstrated.
 [11, 12]
  Further research is needed in this area to 
optimise techniques and define specific patient groups that may benefit.  
 
Conclusion 
 
We have identified two large groups of patients – those with failed BCS and those 
who underwent mastectomy for small foci of DCIS – together accounting for 15% of 
our 8313 patient cohort, where surgical management could be improved. There is a 
pressing need to improve the accuracy of assessment of DCIS extent, particularly for 
those women where mastectomy may otherwise be indicated. In such situations, 
increased utilisation of multiple biopsies to accurately determine disease extent should 
be considered. Similarly, detailed radiological – pathological correlation of the extent 
and nature of the microcalcifications should be ensured at multidiscliplinary meetings. 
Our data provide an evidence-base for benchmarking future practice in this area, 
building from the best performing hospitals to raise standards.
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Appendix 2 
 
UK Breast Screening Units contributing to the Sloane Project 
 
Avon North Derbyshire 
Barking, Havering, Redbridge 
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Barnsley North Lancs & South Cumbria 
Beds and Herts North London* 
Bolton, Bury & Rochdale North Nottinghamshire 
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North & Eastern Devon Wycombe 
North & Mid Hampshire  
North Cumbria * Unit data not included in these analyses 
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Appendix 4 
 
Statistical Methods 
 
The study has three separate elements: 
 
1. Comparison of agreement between pathological and radiological measurement 
of DCIS extent in different operative subgroups 
 
2. Analysis of variation of various parameters in different hospitals 
 
3. Assessment of hospitals’ different operation rates.  
 
1. Comparison of agreement between pathological and radiological measurement of 
DCIS extent in different operative subgroups. 
 
Agreement between pathology and radiology size estimations was assessed using 
Altman Bland difference plots (also known as a Tukey mean-difference plot), where 
the difference between the radiological and pathological size for any individual is 
plotted against the mean of the two values. The systematic bias in any group of paired 
measurements is the mean of all the differences - positive or negative.   
 
We have compared two completely unrelated measurement techniques for assessing 
the extent of DCIS in our patients. Radiological and pathological measurements of 
DCIS extent are made independently – the former at the time of initial diagnosis on 
the basis of the extent of a radiological abnormality (normally calcification.) and the 
latter from the extent of disease as measured on histological tissue sections (glass 
slides) from the excised tissue. The Altman Bland analysis is particularly relevant to 
our study population as it allows an estimate of systematic bias in any particular 
subgroup and the identification of outliers.  It is widely used as a method in the 
analysis of agreement between clinical measurements. 
 
2. Analysis of variation of various parameters in different hospitals 
 
We have restricted this analysis to the top quartile of the hospitals in the audit in terms 
of numbers of patients entered. This is because our median value (10) is very low and 
our distribution has a long tail. The top quartile has a range from 387 to 50 patients 
and within that quartile the distribution of patients is nearly normal. We have attached 
sample charts of our key data groups in a supplementary Excel file to illustrate this.  
 
We should also state that the only meaningful analysis of variance is between one 
subgroup and the parent group (excluding that subgroup) because one subgroups will 
inevitably also vary in counter-step with another. For example, if a hospital does x 
conservation operations then, crudely, there will be two possible outcomes: successful 
or unsuccessful conservation,  y or x-y. It is meaningful to compare the variance of 
one or other of those outcomes with the variance in the parent group among different 
hospitals. But if one subgroup is significantly different then so will be the other. 
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We have used a one tailed Anova test to compare the variance of a particular 
measurable among hospitals: 
 
b) One-tailed ANOVA test 
 
For the pair of data we examined (BCS parent group minus unsuccessful BCS cases v 
unsuccessful BCS cases) we confirmed homogeneity of variances using Hartleys F 
max test giving an F max value of 1.07. This is below the critical value (N=122, 2 
groups, 1.15) at the 0.05 level of significance. There were significant differences in 
the variance of the two BCS subgroups (p=0.0001). We have supplied the descriptive 
analysis for the data underpinning tests including the residual plots. 
 
The assumptions of ANOVA were met as follows:- 
Independence of sample groups was achieved through the selection of groups.  All 
cases were members of only one analysis group. 
 
The data fits well with a normal distribution. Normality was assessed by examination 
of the residual plots from the variance model.  This indicated that the probability of a 
non normal distribution was <0.0001 for successful and failed BCS.  
 
It was not possible to carry out ANOVA analysis of the by-hospital mastectomy 
subgroups because the case numbers were too small. 
 
 
3. Assessment of hospitals’ different operation rates.  
 
We have used  Pearson’s Test to quantify the relationship between a hospital’s overall 
mastectomy rate and its rate of failed BCS and included the output for that analysis.  
 
We have subdivided the top quartile (57 hospitals) into three frequency groups each 
of 19 hospitals for failed BCS and MFSL respectively. It should be noted that there 
was little overlap in the frequency subgroupings for the two adverse outcomes and 
therefore the numbers of patients in each subgroup for each outcome are inevitably 
different. A chi squared test was used to test significance between the frequencies for 
each subgroup in an outcome group. Each frequency subgroup comprised over 1800 
patients.
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Legends 
 
Tables 
 
Table 1: Disease extent (pathological), radiological/pathological size agreement, 
DCIS grade, ER positivity and use of slice radiography relating to operation type. 
 
Table 2: Distribution of different operation types by submitting hospital (top quartile). 
The percentages referred to in the ranges refer to breast conservation and mastectomy 
totals respectively, e.g mastectomy for lesions <20mm  accounted for 3-60% of all 
mastectomies in the different hospitals. 
 
Table 3: Data analysis for high, middle and low frequency hospitals as ranked for 
failed BCS and mastectomy for small tumours respectively. 
 
 
Figures 
 
Figure 1. Accrual profile for patients registered in the audit between 2003 and 2012. 
 
Figure 2. Altman Bland plot for mastectomy patients following failed breast 
conservation surgery. 
Figure 3. Altman Bland plot for mastectomy patients with lesions < 20mm.
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Table 1 
  BCS 1 Op BCS 2 Ops 
BCS followed by 
Mastectomy Primary Mastectomy 
Mastectomy for tumours 
≥20mm 
Mastectomy for 
tumours <20mm  
Number 
a
 3946 1435 799 1680 1969 510  
Median pathology size (mm) 12 17 40 35 42 12  
95% CI (mm) 12-12 16-18 36-40 32-37 40-45 12-13  
Inter Quartile Range (mm) 13·0 15.00 30.00 30.00 30.00 8.00  
Altman Bland Bias (mm)
 b
 2·95 (2·90) -0·32 (0·01) -13·49 (-11·43) 9·9 (9·82) -2·29 (-3·97) 19·86 (18·8)  
% High grade DCIS 58·5 59·3 70·2 77·5 78·1 63·9  
% ER Positive 83·2 79·9 72·8 69·1 69·3 73·7  
Slice radiography (%) 21.0 20·3 21·5 15·1 16·9 18·4  
        
BCS 1 Op – Successful breast conserving surgery by one surgical operation; BCS 2 Ops - Successful breast conserving surgery by two surgical operations; Primary mastectomy – mastectomy as first procedure; ER – oestrogen receptor. 
a 
excludes therapeutic mammoplasty - 47 patients; diagnostic biopsy - 349 patients; successful BCS after more than two operations - 57 patients  
b
 data in brackets refer to specimens with slice radiography      
        
Table 1: Disease extent (pathological), radiological/pathological size agreement, DCIS grade, ER positivity and use of slice radiography relating to operation type. 
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Table 2 
  
BCS 1 Op BCS 2 Ops 
BCS followed by 
Mastectomy Primary Mastectomy 
Mastectomy for 
tumours ≥20mm 
Mastectomy for 
tumours <20mm 
Number of Hospitals 57 57 57 57 57 55 
Range of Cases per Hospital 14-201 4-72 2-38 3-89 7-118 0-49 
Percentage of all (BCS or mastectomy) (median) 65 22 12 63 83 18 
Range (% of all BCS or Mastectomy) 37-85 9-32 3-32 33-96 40-100 0-60 
95% CI 60-68 19-25 11-13 32-37 77-87 13-23 
Inter Quartile Range 14 12 7 23 16 16 
Mean (% of all BCS or Mastectomy) 64.4 22.5 12.4 62.5 80.1 20.7 
Standard Deviation 10.1 7.9 5.9 15.1 13.0 12.5 
BCS 1 Op – Successful breast conserving surgery by one surgical operation; BCS 2 Ops - Successful breast conserving surgery by two surgical operations; Primary mastectomy – mastectomy as first procedure. 
Table 2: Distribution of different operation types by submitting hospital (top quartile). The percentages referred to in the ranges refer to breast conservation and mastectomy 
totals respectively, e.g mastectomy for lesions <20mm  accounted for 3-60% of all mastectomies in the different hospitals.  
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Table 3 
 Ranked for Frequency of Failed BCS 
Ranked for Frequency of MFSL 
 
Frequency Group High Medium Low High Medium Low 
No. of Hospitals 19 19 19 19 19 19 
Total Patients (BCS and Mastectomy) 1856 2539 2296 2005 2121 2565 
No. of patients with failed BCS/MFSL 272 237 123 201 114 61 
Total no. of BCS Cases/Mastectomies 1220 1764 1767 586 640 748 
Mean Frequency of failed BCS/MFSL (%) 22.3 13.4 7.0 34.3 17.8 8.2 
Frequency Range (%) 13.2 - 31.6 10.0 - 13.1 2.6 - 9.9 23.3 - 60.0 12.5 - 23.3 0 - 11.7 
Median Age of Patient 59 60 60 60 60 60 
Median Spec Weight (gms) 42.1 40 35 619.5 591 600 
Central Lesion (%) (all cases in group) 6.6 6.4 6.4 7.2 7.3 5.2 
Central lesion (%) Mx <20mm - - - 13.4 11.4 8.8 
Central lesion (%) Mx ≥20mm - - - 12.3 11.9 13.1 
Median Pathology Size (mm) - all cases 17 16.15 16 17 17 20 
Median Maximum Radiology Size - all cases 18 19 18 17 17 17.5 
High Grade DCIS (%) 62.9 59.6 64.7 65.4 61.7 66.4 
ER positive (%) 82 69 80 62 87 79 
Comedo Necrosis (%) 62.1 68.5 70.6 67.7 66.4 69.9 
Solid Pattern (%) 58 56 64 54 60 62 
Cribriform Pattern (%) 29 33 26 33 29 27 
Micropapillary Pattern (%) 8 5 5 6 6 6 
Altman Bland Bias (mm):       
Successful BCS 1 Operation 2.75 2.73 3.08 3.66 2.1 2.6 
Successful BCS 2 Operations -1.24 1.09 -0.9 0.89 -1.57 -0.92 
Failed BCS -10.64 -15.42 -13.9 -10.37 -12.47 -20.18 
Primary Mastectomy 6.6 8.47 11.7 12.9 8.75 5.47 
Mastectomy lesion ≥20mm -6.65 -3.99 2.1 -3.32 -1.88 -4.13 
Mastectomy lesion <20mm (MFSL) 17.44 20.14 23.5 22.52 17.01 17.72 
BCS 1 Op – Successful breast conserving surgery by one surgical operation; BCS 2 Ops - Successful breast conserving surgery by two surgical operations; Primary mastectomy – mastectomy as first procedure; ER – oestrogen receptor; MSFL – Mastectomy for small lesion. 
 
Table 3: Data analysis for high, middle and low frequency hospitals as ranked for failed BCS and mastectomy for small tumours respectively. 
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Figure 1 
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Figure 2 
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Figure 3 
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SUPPLEMENTARY RESULTS 
 
 
Case distribution: 
 
7537/8313 (84.4%) cases were of pure DCIS; 776 (8.7%) DCIS combined with 
atypical ductal hyperplasia (ADH) and/or lobular in situ neoplasia (LISN); The 
distribution of cases by operation type (mastectomy or BCS) is shown in 
Supplementary Table 1. 
 
Demographics, operation type and tumour grade  
 
218 (2.6%) of patients were under 50 years of age; 5866 (70.7%) were 50-64 years; 
1827 (22.0%) were 65-70 years; and 381 were (4.6%) aged over 70 years and 21 
patients (0.25%) of unknown age. There was no difference in the frequency of 
operation types between the different age groups.  
 
The overall grade distribution (8313 cases) was: high grade 62.0%, intermediate grade 
28.5% and low grade 9.2%, with 0.2% of cases ungraded. Although the under 50 
years age group (a group not screened routinely in the UK NHS BSP) showed less 
high grade disease (55%) in comparison to the 50-64 years age group (63%) this 
difference was not significant (Chi squared test; p=0.25). 
 
Margins 
 
Supplementary Text or Table (online publication only)
Of the patients who had only one operation for BCS 351 (9%) and 137 (3%) had a 
final radial margin of <2mm and <1mm respectively. The median minimum final 
radial margin was 5mm (IQR 6mm). 
 
 
Morphological pattern/architecture: frequency, extent, grade and comedo necrosis 
 
The architectural pattern was recorded in over 7846 cases. A single growth pattern of 
DCIS was reported in 4532 (57%) of cases and two patterns in 2800 cases (36%). The 
most commonly reported descriptions were solid or cribriform and these accounted 
for 88% of single-pattern disease. The distribution of architectural pattern vs grade, 
comedo necrosis and disease extent in addition to ER status and Altman Bland bias is 
shown in Supplementary Table 2. The analysis has been restricted to the 4532 cases 
where a single pattern of DCIS was reported.  
 
Cribriform disease was significantly larger than either solid or micropapillary BCIS 
(T test, p=<0.0001). No difference was seen between the size of solid and 
micropapillary DCIS (T test, p=0.19). Only 310 cases showed a pure micropapillary 
pattern.  
 
There were substantial differences in the percentages of the two more common 
patterns of DCIS (solid and cribriform), grade, comedo necrosis and ER positivity 
among the top quartile of treatment hospitals. There was no correlation between 
grade, comedo necrosis or histological pattern and a hospital’s operative profile.  
 
Extent of DCIS: Grade and ER status 
 
There was a significant difference in the grade distribution between smaller lesions 
15mm and larger lesions (T test; p=<0.0001); there was 50% more high grade 
disease in more extensive lesions. However, there was no significant difference in the 
grade distribution between 15-40mm and >40mm DCIS.  
 
4579 (55%) of cases had recorded ER status and 78.8% of these (n=3581) cases were 
ER positive. ER negative disease was significantly more extensive than ER positive 
disease in the high grade subgroup only (median 23.0mm vs 20.0mm; IQRs  22.0 vs 
23.0) (T test, p=<0.0001).  
 
 
SUPPLEMENTARY DISCUSSION 
 
 
Pathological variables 
 
A pure architectural pattern of DCIS was recorded in over half of our patients. Three 
main points emerge: solid pattern DCIS is very commonly high grade and associated 
with comedo necrosis, while cribriform DCIS is more commonly a smaller lesion and 
more frequently low grade. Notably, and in contrast to a previous report, we have no 
evidence that micropapillary DCIS is a particularly extensive or multicentric lesion. 
[1]
 
 
Invasive breast cancer is graded by assessing three variables and consistency of 
grading is considered acceptable with published kappa values for overall consistency 
(j value) for grade 1 and grade 3 of 0.45 and 0.63, respectively. 
[2, 3]
  Consistency of 
grading and classifying DCIS where a single feature (cytonuclear morphology) is used 
is poor in comparison (Schuh et al,). 
[4]
  Although comedo necrosis has been shown to 
be of prognostic significance 
[5]
 this feature is not routinely combined with the single-
feature cytonuclear grade to improve discrimination in UK practice and although 
assessment of the pattern of DCIS has been shown to add value to this exercise, mixed 
patterns are seen frequently and therefore is difficult to apply in practice. 
[6]
 A major 
goal of the Sloane Project is to improve prognostic assessment of DCIS and reviewing 
prognostic algorithms such as the Van Nuys Prognostic Index 
[7]
 will be possible as 
more complete recurrence data become available.
 
Data on margin width will be of 
considerable interest at that time too. 
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Supplementary Legends 
 
 
Supplementary Table 1: Disease types in mastectomies and breast conservation cases. 
 
Supplementary Table 2: Frequency of pathological variables by architectural pattern 
of  DCIS 
 Supplementary Table 1 
       
  ALL % Mastectomy 
a
 % BCS 
b
 % 
Pure DCIS 7537 90.7 2282 92.1 5255 90.1 
DCIS + ADH 323 3.9 16 0.6 307 5.3 
DCIS + LISN 304 3.7 84 3.4 220 3.8 
DCIS + ADH + LISN 149 1.8 97 3.9 52 0.9 
Total 8313 100 2479 100 5834 100 
a
 Includes 799 failed 
BCS Patients       
       
b
 Excludes 799 failed 
BCS Patients       
       
Supplementary Table 1: Disease types in mastectomies and breast conservation cases.  
 
Supplementary Table 2 
    Grade (No /(%))       
  No 
Frequency 
(%) 
Size  (median - mm)/ 
95%CI Low Intermediate High Ungraded 
Comedo Necrosis No 
(%) ER Pos No (%) 
Altman Bland 
Bias 
Solid 2573 57 16 / (16-17) 62 (2) 454 (18) 1985 (77) 71 (3) 2040/2487 (82) 963/1396 (68) 3·68 
Cribriform 1398 31 10·5 / (10·0-11·0) 294 (22) 562 (42) 488 (36) 54 (4) 692/1304 (53) 678/775 (87) 4·99 
Micropapillary 310 7 17 / (15-20) 68 (22) 74 (24) 125 (40) 43 (14) 169/281 (60) 118/145 (81) 4·96 
Others 251 6                 
Total 4532          
           
Supplementary Table 2: Frequency of pathological variables by architectural pattern of  DCIS      
 
 
